-
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Amherst, Brooklyn, New York, Port Jefferson Station
-
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Amherst, Brooklyn, New York, Port Jefferson Station
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
NCT06473597 ·
Phase: Phase 4 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: Brooklyn
-
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07674654 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Amherst, Brooklyn, Commack, Manlius
-
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675 ·
Phase: Phase 3 ·
Ages: 12 Years to 17 Years ·
Sex: All (male and female)
· New York: Amherst, Commack
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· New York: Amherst, Commack
-
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· New York: Commack
-
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505 ·
Phase: Phase 3 ·
Ages: 12 Years to 17 Years ·
Sex: All (male and female)
· New York: Amherst
-
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· New York: Amherst, New York
-
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· New York: Brooklyn, The Bronx, Williamsville
-
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07645924 ·
Phase: Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: Amherst, Brooklyn, Commack, Manlius
-
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· New York: New York
-
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466 ·
Phase: Phase 3 ·
Ages: 18 Years to 45 Years ·
Sex: Female
· New York: Rochester, The Bronx
-
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
NCT06995729 ·
Phase: Phase 1 ·
Ages: 6 Years to 11 Years ·
Sex: All (male and female)
· New York: Port Jefferson Station
-
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
NCT07061847 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· New York: Great Neck
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
NCT06972056 ·
Phase: Phase 4 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· New York: Kingston, Manhasset, New York
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· New York: Amherst, The Bronx
-
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· New York: Amherst, Commack, New York, Port Jefferson Station
-
MMA Embolization for Refractory Chronic Migraine
NCT06735833 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: New York, Stony Brook
-
RELAXaHEAD for Headache Patients (Phase III)
NCT06077838 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 16 Years to 80 Years ·
Sex: All (male and female)
· New York: New York
-
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· New York: Amherst, Commack, Lake Success, Mineola
-
Responding With Evidence and Access for Childhood Headaches
NCT05889624 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· New York: Amherst
-
Study of EVO756 in Adults With Migraine
NCT07616128 ·
Phase: Phase 2 ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female)
· New York: Amherst
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
NCT05125302 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· New York: Amherst, Mount Kisco, New York, Port Jefferson Station